Clinical trials: Peritoneum Cancer
Fallopian Tube Cancer, Ovarian Cancer
Monoclonal Antibody Vaccine Therapy in Treating Patients With Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer
RATIONALE: Vaccines made from monoclonal antibodies combined with tumor cells may make the body build an immune response to kill tumor cells.
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Trial name
- NCT00058435
- Testing
- abagovomab
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Urinary Bladder Neoplasms, Carcinoma, Transitional Cell
A Phase 1 Study of CC-486 as a Single Agent and in Combination With Carboplatin or ABI-007 in Subjects With Relapsed or Refractory Solid Tumors
The purpose of the study is to evaluate the safety and to define the Maximal Tolerated Dose (MTD) or the Maximal Administered Dose (MAD) of oral azacitidine as a single agent and in combination with carboplatin (CBDCA) or…
- Conditions
- Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ovarian Neoplasms, Fallopian Tube Neoplasms
- Trial name
- NCT01478685
- Testing
- CC-486, Carboplatin, ABI-007
- Where
- 13 sites in United States, France and 2 more
- Volunteers
- 169 people
- Sponsor
- Celgene
Breast Carcinoma, Fallopian Tube Carcinoma
Serial Imaging of the Novel Radiotracer [^18F] FLuorthanatrace ([^18F] FTT) by PET/CTF
This phase I trial studies how well fluorine F 18 fluorthanatrace positron emission tomography (PET)/computed tomography (CT) works in patients with solid tumors.
- Conditions
- Breast Carcinoma, Fallopian Tube Carcinoma, Ovarian Carcinoma, Primary Peritoneal Carcinoma
- Trial name
- NCT03604315
- Testing
- Computed Tomography, Fludeoxyglucose F-18, Fluorine F 18 Fluorthanatrace
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- M.D. Anderson Cancer Center
Advanced Ovarian Carcinoma, Stage IIIC Fallopian Tube Cancer AJCC v8
Prehabilitation for Stage IIIC-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients
This clinical trial evaluates whether a prehabilitation program started at the time of neoadjuvant chemotherapy will affect surgical recovery in patients with stage IIIC-IV ovarian, fallopian tube, or primary peritoneal cancer.
- Conditions
- Advanced Ovarian Carcinoma, Stage IIIC Fallopian Tube Cancer AJCC v8, Stage IIIC Ovarian Cancer AJCC v8, Stage IIIC Primary Peritoneal Cancer AJCC v8
- Trial name
- NCT05047926
- Testing
- Behavioral Counseling, Nutritional Supplement Drink, Physical Activity
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- Mayo Clinic
Ovarian Cancer
Sorafenib + Topotecan for Platinum-Resistant Recurrent Ovarian Cancer
This multi-institutional phase I/II clinical trial will test the tolerability and efficacy of the combination sorafenib and topotecan in patients with recurrent ovarian cancer, which is platinum-resistant (recurrence within 6…
- Trial name
- NCT00526799
- Testing
- Sorafenib, Topotecan
- Where
- 8 sites in United States
- Volunteers
- 30 people
- Sponsor
- Daniela Matei, MD
Advanced Solid Tumors, Ovarian Cancers
Allogeneic B7H3 CAR-γδT Cell Therapy for Advanced Solid Tumors
γδT cells can directly recognize non-peptide tumor antigens, such as IPP phosphorylated metabolites, without relying on specific major histocompatibility complexes (MHCs).
- Conditions
- Advanced Solid Tumors, Ovarian Cancers, Peritoneal (metastatic) Cancer
- Trial name
- NCT06825455
- Testing
- Fludarabine, Cyclophosphamide, B7H3 CAR-γδT cells
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Peking University
Gastric Cancers
Tissue Procurement for Gastric Cancer, Gastrointestinal Stromal Tumors (GIST), Esophageal Cancer, Pancreas Cancer, Hepatocellular Cancer, Biliary Cancer, Neuroendocrine, Peritoneal Mesothelioma, Anal Cancer and Colorectal Cancer in Patients Undergoing Surgery or Biopsy
The purpose of this study is to collect and store normal and malignant tissue from patients with gastric cancer, GIST, esophageal cancer, pancreas cancer, hepatocellular cancer, biliary cancer, neuroendocrine, peritoneal…
- Trial name
- NCT01416714
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- University of Chicago
Peritoneal Carcinomatosis
FloSeal in CRS and HIPEC
Introduction Modern treatment of peritoneal carcinomatosis (PC) combines an aggressive cytoreductive surgery (CRS) of all macroscopic disease and hyperthermic intraperitoneal chemotherapy (HIPEC) performed at the time of surgery.
- Trial name
- NCT01957852
- Testing
- FloSeal
- Where
- Canada
- Volunteers
- 86 people
- Sponsor
- Maisonneuve-Rosemont Hospital
Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma
Propranolol Hydrochloride and Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
This early phase I trial studies giving propranolol hydrochloride with standard chemotherapy in treating patients with ovarian, primary peritoneal, or fallopian tube cancer.
- Conditions
- Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma
- Trial name
- NCT01504126
- Testing
- Chemotherapy, Propranolol Hydrochloride, Quality-of-Life Assessment
- Where
- 7 sites in United States
- Volunteers
- 32 people
- Sponsor
- M.D. Anderson Cancer Center
Ovarian Cancer, Fallopian Tube Cancer
A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab
This study is researching an investigational drug called REGN5668 : alone or, combined with cemiplimab (also known as REGN2810) or, combined with both cemiplimab and fianlimab (also known as REGN3767), or combined with ubamatamab…
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Endometrial Cancer
- Trial name
- NCT04590326
- Testing
- REGN5668, Cemiplimab, Ubamatamab
- Where
- 28 sites in United States, Belgium and 3 more
- Volunteers
- 612 people
- Sponsor
- Regeneron Pharmaceuticals
Gastric Cancer Stage IV, Peritoneal Metastasis
Conversion Surgery for Gastric Cancer With Peritoneal Metastases (CONVERGENCE)
The goal of this clinical trial is to evaluate the impact of conversion surgery on overall survival (OS) in patients with gastric cancer peritoneal metastases (GCPM) who show a good response to preoperative systemic therapy…
- Trial name
- CONVERGENCE (NCT07241715)
- Testing
- Conversion Surgery, Systemic Therapy/Standard of Care
- Where
- Singapore
- Volunteers
- 300 people
- Sponsor
- National University Hospital, Singapore
Peritoneal Carcinomatosis
A Nomogram to Predict Major Postoperative Complications After Cytoreductive Surgery and HIPEC Based on Pre and Peroperative Criteria: Which Patient Require Intensive Monitoring?
In this study, the investigators tend to highlight pre and peroperative factors that predict major postoperative complication after a surgery for resection of peritoneal carcinomatosis.
- Trial name
- NCT05547568
- Testing
- Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy
- Where
- France
- Volunteers
- 219 people
- Sponsor
- CHU de Reims
Epithelial Ovarian Cancer, Fallopian Tube Cancer
GANNET53: Ganetespib in Metastatic, p53-mutant, Platinum-resistant Ovarian Cancer
Epithelial ovarian cancer (EOC) is the most lethal gynaecological malignancy causing 41900 deaths annually in Europe. The predominance of aggressive Type II tumours, which are characterised by a high frequency of p53 mutations…
- Conditions
- Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
- Trial name
- NCT02012192
- Testing
- Ganetespib, Paclitaxel
- Where
- 10 sites in Austria, Belgium and 2 more
- Volunteers
- 133 people
- Sponsor
- Medical University Innsbruck
Peritoneal Mesothelioma, Gestational Trophoblastic Tumor
IMMUNORARE5: A National Platform of 5 Academic Phase II Trials Coordinated by Lyon University Hospital to Assess the Safety and the Efficacy of the IMMUNOtherapy With Domvanalimab + Zimberelimab Combination in Patients With Advanced RARE Cancers
Immune checkpoint inhibitors (ICI) have revolutionized the management of advanced cancers. However, most rare cancers have been excluded from this progress due to the lack of clinical trials involving these diseases.
- Conditions
- Peritoneal Mesothelioma, Gestational Trophoblastic Tumor, Anaplastic Thyroid Carcinomas, Gastroenteropancreatic Neuroendocrine Tumor
- Trial name
- IMMUNORARE5 (NCT06790706)
- Testing
- DOMVANALIMAB + ZIMBERELIMAB, DOMVANALIMAB + ZIMBERELIMAB + FOLFOX-4
- Where
- 15 sites in France
- Volunteers
- 27 people
- Sponsor
- Hospices Civils de Lyon
Male Breast Cancer, Recurrent Breast Cancer
Carboplatin, Gemcitabine Hydrochloride, and Mifepristone in Treating Patients With Advanced Breast Cancer or Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
This phase I trial studies the side effects and best dose of gemcitabine hydrochloride and mifepristone when given together with carboplatin in treating patients with breast cancer that is metastatic or cannot be removed by…
- Conditions
- Male Breast Cancer, Recurrent Breast Cancer, Recurrent Fallopian Tube Cancer, Recurrent Ovarian Epithelial Cancer
- Trial name
- NCT02046421
- Testing
- mifepristone, carboplatin, gemcitabine hydrochloride
- Where
- 2 sites in United States
- Volunteers
- 31 people
- Sponsor
- University of Chicago
Gastrointestinal Cancer
STRONG Program for Cancer Patients
The purpose of the study is to assess the feasibility and participant satisfaction with the Support through Remote Observation and Nutrition Guidance (STRONG) program.
- Trial name
- NCT05649969
- Testing
- Consultations with Moffitt Dietician, Daily Food Intake Diary with Fitbit smartphone application, Questionnaires
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Colorectal Cancer, Peritoneal (Metastatic) Cancer
Comparing 18F-FAPI PET-Guided Abdominal Radiotherapy Combined With Second-Line Standard Therapy and Cadonilimab Versus Second-Line Standard Therapy in Colorectal Cancer With Peritoneal Metastasis
Main objective: 1. To compare the objective response rate (ORR) of 18F-FAPI PET-guided abdominal region radiotherapy combined with second-line standard treatment versus cadonilimab and second-line standard treatment in the…
- Conditions
- Colorectal Cancer, Peritoneal (Metastatic) Cancer, FAPI PET
- Trial name
- NCT07079462
- Testing
- Radiotherapy followed by immunotherapy and chemotherapy, Chemotherapy (control)
- Where
- 2 sites in China
- Volunteers
- 40 people
- Sponsor
- Fudan University
Ovarian Neoplasms, Peritoneal Neoplasms
Tolerance, Safety, Efficacy, and Pharmacokinetics of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) Using Paclitaxel for Platinum-resistant Recurrent Ovarian Cancer
The purpose of this study is to evaluate the tolerance, safety, efficacy, and pharmacokinetics of pressurized intraperitoneal aerosol chemotherapy (PIPAC) with paclitaxel in patients with platinum-resistant recurrent ovarian…
- Trial name
- NCT07273396
- Testing
- Pressurized intraperitoneal aerosol chemotherapy (PIPAC) using paclitaxel
- Volunteers
- 53 people
- Sponsor
- Seoul National University Hospital
Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma
AVB-S6-500 and Durvalumab in Treating Patients With Platinum-Resistant or Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
This trial studies the side effects and best dose of AVB-S6-500 when given together with durvalumab in treating patients with ovarian, fallopian tube, or primary peritoneal cancer that is resistant to platinum therapy or has come…
- Conditions
- Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Recurrent Fallopian Tube Carcinoma
- Trial name
- NCT04019288
- Testing
- Batiraxcept, Durvalumab
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- M.D. Anderson Cancer Center
Ovarian Cancer, Fallopian Tube Cancer
The Activity of TroVax® Versus Placebo in Relapsed Asymptomatic Ovarian Cancer
The purpose of this trial is to assess the effectiveness of TroVax® compared to placebo in extending the time to progression in patients with asymptomatic relapsed platinum resistant ovarian, fallopian tube or primary peritoneal…
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
- Trial name
- TRIOC (NCT01556841)
- Testing
- TroVax®
- Where
- 12 sites in United Kingdom
- Volunteers
- 94 people
- Sponsor
- University College, London
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.